Overview

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Status:
Not yet recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.
Phase:
Phase 1
Details
Lead Sponsor:
Meryx, Inc.